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Abstract 
Background: Campylobacter is a genus of bacteria that has been isolated from the gastrointestinal tract of humans 
and animals, and the environments they inhabit around the world. Campylobacter adapt to new environments by 
changes in their gene content and expression, but little is known about how they adapt to long-term human coloni-
zation. In this study, the genomes of 31 isolates from a New Zealand patient and 22 isolates from a United Kingdom 
patient belonging to Campylobacter jejuni sequence type 45 (ST45) were compared with 209 ST45 genomes from 
other sources to identify the mechanisms by which Campylobacter adapts to long-term human colonization. In addi-
tion, the New Zealand patient had their microbiota investigated using 16S rRNA metabarcoding, and their level of 
inflammation and immunosuppression analyzed using biochemical tests, to determine how Campylobacter adapts to 
a changing gastrointestinal tract.
Results: There was some evidence that long-term colonization led to genome degradation, but more evidence that 
Campylobacter adapted through the accumulation of non-synonymous single nucleotide polymorphisms (SNPs) and 
frameshifts in genes involved in cell motility, signal transduction and the major outer membrane protein (MOMP). The 
New Zealand patient also displayed considerable variation in their microbiome, inflammation and immunosuppres-
sion over five months, and the Campylobacter collected from this patient could be divided into two subpopulations, 
the proportion of which correlated with the amount of gastrointestinal inflammation.
Conclusions: This study demonstrates how genomics, phylogenetics, 16S rRNA metabarcoding and biochemical 
markers can provide insight into how Campylobacter adapts to changing environments within human hosts. This 
study also demonstrates that long-term human colonization selects for changes in Campylobacter genes involved in 
cell motility, signal transduction and the MOMP; and that genetically distinct subpopulations of Campylobacter evolve 
to adapt to the changing gastrointestinal environment.
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Background
Campylobacter is a genus of bacteria that has been iso-
lated from the gastrointestinal tract of humans and other 
animals around the world [1], and from the environments 
these animals inhabit [2]. Some Campylobacter spe-
cies are host generalists, colonizing a wide range of host 
species [3], others are host-specific [4], and some are 
pathogenic to the animals they colonize [5]. Population 
genomics and animal studies have demonstrated that 
Campylobacter adapts to hosts by changing its gene con-
tent and expression [6, 7]. As long-term Campylobacter 
colonization in humans is rare, few studies have investi-
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Previously, a patient in New Zealand was identified 
that had been excreting the same strain of Campylobac-
ter, C. jejuni sequence type (ST) 45, for over a decade [8]. 
The patient had been diagnosed with common variable 
immune deficiency (CVID) and had suffered from daily 
diarrhea that varied in severity. Previous genomic analy-
sis and antimicrobial susceptibility testing of Campy-
lobacter isolates collected from the patient determined 
that the patient was consistently colonized with Campy-
lobacter over this time period, and that the Campylobac-
ter had developed resistance to the antimicrobial agents 
the patient was prescribed. However, it was unclear 
to what extent the Campylobacter was contributing to 
the patient’s diarrhea. In this study we compared the 
genomes of ST45 isolates collected from the patient to 
those collected from other sources, including another 
patient from the United Kingdom with long-term colo-
nization, to investigate how Campylobacter had adapted 
to human hosts, and used 16S rRNA metabarcoding and 
biochemical markers to investigate changes in microbial 




The New Zealand patient submitted three fecal and three 
serum samples over five months. Three Campylobacter 
isolates were collected from the first fecal sample, and 
six were collected from the second and third samples. 
These 15 isolates were combined with the 16 previously 
sequenced from this patient. An additional 231 C. jejuni 
ST45 isolates were downloaded and passed the quality 
control thresholds, including 22 from a long-term patient 
from the United Kingdom (Additional file 1).
ST45 pan‑genome analysis
The 262 ST45 genomes contained a pan-genome of 3041 
genes and a core-genome of 1459 genes. The pan-genome 
also contained 603 pseudogenes, 206 of which the pseu-
dogene or original gene were found in more than 95% 
of isolates. PlasmidFinder identified a plasmid replicon 
(IncFII) in one of the ST45 isolates, and RFPlasmid found 
evidence of plasmid-associated contigs in 109 contigs 
from 50 ST45 isolates. Amongst the plasmid-associated 
contigs, three contained antimicrobial resistance (AMR) 
genes, four contained virulence genes, fourteen were 
conjugative, six were mobile and 89 were non-mobile. 
None of the isolates collected from the New Zealand 
patient contained plasmid-associated contigs, but two of 
the isolates from the United Kingdom patients did. How-
ever, they were non-motile and contained no AMR or 
virulence genes.
Gene frequency analysis did not find any evidence of 
specific genes or pseudogenes associated with the 53 
long-term Campylobacter patient isolates when com-
pared to the 209 other ST45 isolates or the subset of 
145 other human ST45 isolates investigated, and linear 
regression analysis found that the number of genes was 
not significantly associated with source (p = 0.2216) or 
country (p = 0.9765). The number of pseudogenes was 
also not significantly associated with source (p = 0.101), 
but was significantly associated with country (p = 0.0114), 
with isolates from the United States containing more 
pseudogenes. This difference was small and likely due to 
sampling (Additional file 2).
All isolates collected from the long-term Campylobac-
ter patients contained the blaOXA-61 beta-lactamase gene 
[10] and the T86I mutation in the gyrA gene associated 
with fluoroquinolone resistance [11], as did 152 and two 
of the 209 other ST45 isolates, respectively. Frameshift 
and SNP analysis demonstrated that the T86I mutation 
was the only mutation associated with long-term Campy-
lobacter patient isolates, when compared to all the other 
ST45 isolates or just the other human ST45 isolated 
investigated. All isolates collected from the New Zealand 
patient and two non-patient ST45 isolates contained the 
A2074T mutation in the 23S rRNA gene associated with 
macrolide resistance [12]. One of the isolates collected 
from the United Kingdom patient contained the A2075G 
mutation in the 23S rRNA gene. No long-term patient-
specific virulence genes were identified.
Phylogenetic analysis of the ST45 isolates from different 
sources and countries demonstrated that the sequence 
type is very diverse (Fig. 1). Clade analysis identified 29 
clades amongst the 262 ST45 isolates. Thirteen of these 
clades consisted of isolates from multiple sources, whilst 
the remaining clades consisted of isolates from the same 
source. However, only three of these clades contained 
more than one non-human source. The isolates from 
the New Zealand patient were in the same clade as iso-
lates from water, ovine, poultry and other human iso-
lates (Clade 18), whilst no other isolates were found in 
the same clade as the United Kingdom long-term patient 
(Clade 2) (Additional file  3). A closer examination of 
clade 18 revealed that the isolates collected from the New 
Zealand patient shared 2–123 SNPs with each other, and 
22–239 SNPs with other isolates in this clade. They were 
most closely related to two genomes from New Zealand 
human sources. These two genomes were the only other 
ST45 isolates that contained the A2074T mutation in the 
23S rRNA gene.
New Zealand patient phylogenetics
SNP analysis identified 248 non-recombinant SNPs 
amongst the 31 isolates collected from the New Zealand 
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patient. TempEst found tip dates and distance were 
correlated  (R2 = 0.92) (Additional file  4). Phylogenetic 
modeling estimated that these isolates contained a 
median substitution rate of 3.69 ×  10–6 substitutions 
 site−1   year−1 (95% HPD interval: 2.87–4.49 ×  10–6 sub-
stitutions  site−1   year−1) and shared a common ancestor 
on 09/05/2004 (median, 95% HPD interval: 11/12/2002–
16/07/2005). The sampled ancestor model did not iden-
tify isolates that represented ancestors of other isolates 
collected from the patient.
Phylogenetic analysis revealed that two clades had 
evolved within the New Zealand patient representing 
separate subpopulations (Fig.  2). These clades shared a 
common ancestor on 08/07/2010 (median, 95% HPD 
interval: 19/09/2009–20/03/2011). Comparative genetic 
analysis revealed that clade A was associated with the 
rsmD gene, involved in DNA replication and repair; and 
clade B was associated with the dcuB gene, involved in 
the transport of C4-dicarboxylates into the cell. These 
genes were classified as pseudogenes in the other clade 
due to frameshifts. Two additional frameshifts and eleven 
non-synonymous SNPs in ten genes differenced between 
the clades. These genes varied in function (Additional 
file 5).
Linear regression modeling found that date of col-
lection was not associated with the number of genes 
Fig. 1 Maximum likelihood tree of 262 ST45 isolates. Colored bars represent isolate metadata and the presence-absence matrix represents 
antimicrobial resistance genes
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(p = 0.0635) or pseudogenes (p = 0.0501) (Additional 
file 6). Clades were not associated with different number 
of genes (p = 0.566) or pseudogenes (p = 0.539).
United Kingdom patient phylogenetics
SNP analysis identified 122 non-recombinant SNPs 
amongst the 22 isolates collected from the United King-
dom patient. Phylogenetic modeling estimated that 
these isolates contained a median substitution rate of 
1.96 ×  10–6 substitutions  site−1   year−1 (95% HPD inter-
val: 1.51–2.44 ×  10–6 substitutions  site−1   year−1) and 
shared a common ancestor on 17/04/1999 (median, 
95% HPD interval: 29/11/1997–23/05/2000) (Additional 
file 7). The sampled ancestor model identified three iso-
lates (median, 95% HPD interval: 1–4) that represented 
ancestors of other isolates collected from the patient. 
Linear regression modeling found that date of collec-
tion was negatively associated with the number of genes 
(p = 0.0129) and positively associated with the number of 
pseudogenes (p = 0.00175) (Additional file 8).
Campylobacter DNA replication and repair
DNA replication and repair mechanisms in Campylobac-
ter involves 27 genes. 54 mutations were identified that 
differed between isolates collected from the New Zealand 
and United Kingdom patients (Additional file  9). The 
gene with the largest number of mutations was the mutS 
gene (n = 20).
Long‑term within human selection
Isolates from the New Zealand patient had a pangenome 
of 1722 genes and an accessory genome of 86 genes, 
whilst the isolates collected from the United Kingdom 
patient had a pangenome of 1743 genes and an acces-
sory genome of 103 genes. Analysis of gene loss over 
the course of colonization identified six genes from the 
New Zealand patient isolates and five from the United 
Kingdom patient isolates that were stably-lost over time. 
However, neither these genes nor the rest of the acces-
sory genome were associated with any functional group 
(Additional file 10).
The isolates collected from the New Zealand patient 
shared 134 core non-synonymous SNPs and 23 core 
frameshifts in 92 genes, whilst the isolates collected from 
the United Kingdom patient shared 88 core non-synony-
mous SNPs and 31 core frameshifts in 81 genes. Of these, 
23 non-synonymous SNPs and two frameshifts from the 
New Zealand patient isolates, and 15 non-synonymous 
SNPs and six frameshifts from the United Kingdom 
patient isolates were stably-inherited. In both patients’ 
isolates, cell motility (COG group N) and signal trans-
duction mechanisms (COG group T) were the functional 
groups with the highest proportion of genes containing 
these mutations (Fig.  3). In addition, some genes con-
tained multiple non-synonymous SNPs and frameshifts 
(Additional file  11). The porA and ccmL genes were the 
only gene that had more than five of these mutations 
amongst isolates collected from both patients.
Fig. 2 Maximum clade credibility tree of 31 ST45 isolates collected from the same New Zealand patient
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16S rRNA metabarcoding of bacterial species
The three fecal microbiota samples from the New Zea-
land patients displayed a large amount of variation in 
the proportion of each bacterial taxa present (Fig.  4). 
The Campylobacter concentrations were not directly 
correlated to the microbiota makeup, likely due to var-
iations in the bacterial concentration of fecal samples.
Biochemical and serological tests
The New Zealand patient tested negative for anti-
Campylobacter antibodies (Table  1), and had low 
immunoglobulin levels that were consistent with their 
immunosuppressive disease [13] and prior history [8]. 
The concentration of calprotectin was directly propor-
tional to the number of isolates from clade B (Fig. 5). 
No other associations between the biochemical results, 
microbiota results, Campylobacter concentration and 
the proportion of each subpopulation were identified.
Discussion
Long-term colonization of human patients places selec-
tive pressure on Campylobacter. Non-synonymous 
SNPs and frameshifts were found in multiple genes 
from Campylobacter isolates collected from the New 
Zealand and United Kingdom patients, especially in 
genes involved in motility and signal transduction 
mechanisms. Two genes were found that had more 
than five of these mutations in both patients: the porA 
gene that encodes the major outer membrane protein 
(MOMP) and the ccmL gene that encodes the multi-
ligand binding chemoreceptor (CcmL). Previous work 
on isolates from the New Zealand patient demonstrated 
that they varied in motility, possibly to evade phago-
cytes [8]; whilst studies on Campylobacter collected 
from the same patients within 24-h demonstrated vari-
ation in motility and chemotaxis genes [14, 15]. This 
suggests that long-term colonization is selecting for 
changes in Campylobacter motility, signal transduction 
Fig. 3 Bar plots of the proportion of genes of each functional group that contained non-synonymous SNPs or frameshifts (A, B) and 
stably-inherited SNPs or frameshifts (C, D) in the New Zealand (A, C) and United Kingdom (B, D) patients
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Fig. 4 Bar plot of the proportion of the New Zealand patient’s microbiota, identified through 16S rRNA profiling, comprised of detectable bacterial 
phyla (A) and genera (B). Bacterial genera that represented less than one percent of the microbiota were placed in the ‘other’ category
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(particularly chemotaxis) and membrane proteins, pos-
sibly to evade host defenses.
Populations of bacteria are continuously accumulat-
ing mutations: canonically, if they are beneficial then 
those containing them will thrive and the mutation will 
increase in frequency, whilst if they are deleterious those 
containing them will struggle and the mutation will even-
tually disappear. However, Ramiro et al. [16] investigated 
Escherichia coli colonizing the gut of mice over 190 days 
and found that beneficial mutations increased in fre-
quency but were not fixed in the population, and slightly 
deleterious mutations remained in the population for 
extended periods of time, possibly by the variable mouse 
gut buffering their deleterious effects. In this study, 
mutations were observed that were stably-inherited 
within the Campylobacter populations of the long-term 
patients, especially in those involved in cell motility and 
signal transduction. These Campylobacter were col-
lected over longer time periods than Ramiro et al. experi-
ments, possibly allowing these beneficial mutations to 
be fixed within the population or the Campylobacter 
were exposed to larger selective sweeps than the E. coli. 
However, a large number of mutations were observed 
in isolates that were not fixed within the Campylobacter 
population, suggesting that the human gastrointestinal 
tract allows for variation in many Campylobacter genes, 
but over time selective sweeps select for specific genetic 
variants. Nevertheless, we cannot rule out the possibil-
ity that many of the stably-inherited mutations were the 
result of “genetic hitchhiking” [17].
The isolates collected from the New Zealand and 
United Kingdom patients both belonged to ST45. How-
ever, within this sequence type the isolates from each 
patient were distantly related, allowing us to identify 
mutations specific to long-term colonization by com-
paring isolates from these patients to ST45 from other 
sources. Genetic comparisons identified one mutation 
associated with long-term patient colonization, T86I 
in the gyrA gene. This mutation is the most common 
cause of quinolone resistance in C. jejuni [11], and the 
New Zealand patient [8] and likely the United Kingdom 
patient [9] were prescribed quinolones, selecting for 
this mutation. A large number of other genes contained 
mutations in the New Zealand and United Kingdom 
patient isolates. However, the mutations either differed 
between isolates from each patient or were found in mul-
tiple other ST45 isolates. This suggests that apart from 
quinolone resistance, long-term human colonization 
Table 1 Biochemical, serological and Campylobacter parameters for three samples collected over five months from the same patient
Sample Measurement 1 2 3 Normal range













C-reactive protein mg/L 0.84 1.45 1.13  < 5.0
IgA g/L  < 0.2  < 0.2  < 0.2 0.7–4.0
IgG g/L 3.9 4.5 4.7 7.0–16.0
IgM g/L  < 0.2  < 0.2  < 0.2 0.4–2.3
anti-Campylobacter IgA Titer Negative Negative Negative Negative
anti-Campylobacter IgG Titer Negative Negative Negative Negative
anti-Campylobacter IgM Titer Negative Negative Negative Negative
Campylobacter concentration cfu/g 1.38 ×  107 1.48 ×  107 1.08 ×  106 0
Proportion Campylobacter 0.111 0.053 0.001 0
Clade A isolates 0/3 3/6 5/6 0
Fig. 5 Scatterplots of the number of the proportion of isolates 
collected from clade A versus the fecal calprotectin concentration for 
three samples collected from the New Zealand patient
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selected for changes in particular genes, but not specific 
mutations.
Bacteria can adapt to environments by both gene loss 
and gene acquisition. Gene loss may increase the fitness 
of the bacteria by decreasing resource expenditure on 
unnecessary cellular processes [18], whilst gene acqui-
sition may allow the bacteria to gain cellular processes 
to thrive in the environment [19]. Previous studies on 
long-term Pseudomonas aeruginosa cystic fibrosis (CF) 
[20] and Salmonella enterica [21] infections found that 
gene loss outweighed gene acquisition over the course 
of these infections. However, Bayjaynov et al. [22] inves-
tigated long-term colonizing E. faecium strains and 
found similar amounts of gene loss and gene acquisi-
tion. In our study, several genes were identified that were 
stably-lost over the course of colonization in the New 
Zealand and United Kingdom patients, and there was 
some evidence of the total number of genes decreasing 
over time. However, no functional group was overrepre-
sented in the accessory genome, suggesting that genome 
reduction is not the main way Campylobacter adapts to 
long-term colonization. Gene loss could have occurred 
between acquisition and isolation of the first isolate, but 
there was no evidence that the long-term patients had 
smaller number of genes compared to the other human 
ST45 isolates. This is a similar observation to long-term 
E. faecium colonization rather than to P. aeruginosa or S. 
enterica infections, namely evidence of similar amounts 
of gene loss and gene gain. Further research is required 
to determine if this is due to the different biology of these 
bacteria, different environments, or different types of 
infection.
In the New Zealand patient, we identified two geneti-
cally distinct clades or subpopulations of Campylobacter. 
In CF infections, divergence of P. aeruginosa subpopula-
tions has been reported prior to infection [23] and within 
the host [24]. Analysis of long-term E. faecium coloniza-
tion has demonstrated the presence of multiple lineages 
within the gastrointestinal tract of humans, but these 
lineages diverged prior to colonization [22]. Phylogenetic 
analysis suggests that the two Campylobacter subpopu-
lations diverged between 2009 and 2011, after the first 
isolate was collected from the patient in 2006, indicating 
that the subpopulations diverged within the host. There 
is evidence of multiple subpopulations coexisting prior 
to this divergence in the New Zealand patient, and in 
the isolates collected from the United Kingdom patient, 
but these patients were not sampled frequently during 
these time periods, preventing further analysis of these 
subpopulations.
The competitive exclusion principle states that no two 
species can occupy the same niche [25]. Accordingly, 
the subpopulations of Campylobacter found within the 
patient are likely to have distinct niches. In CF patients, 
the presence of multiple subpopulations has been attrib-
uted to the bacterium accumulating mutations and phe-
notypically adapting to different environments within the 
human lung [26]. There is evidence of this when looking 
at the genetic differences between the two Campylobac-
ter lineages found within the human host, specifically 
the dcuB gene that encodes a fumarate/succinate active 
antiporter under low oxygen conditions that can also 
import aspartate [27]. Succinate concentrations in the 
gastrointestinal tract have been shown to increase during 
gut dysbiosis [28] and inflammation [29], but it remains 
to be determined if these conditions affect fumarate or 
aspartate concentrations. The New Zealand patient’s gas-
trointestinal tract showed a large amount of variation in 
inflammation plus variation in the microbiota composi-
tion and these may be influencing the concentration of 
succinate and possibly other metabolites. The concen-
tration of calprotectin was negatively associated with 
the proportion of isolates made up of the lineage miss-
ing dcuB, suggesting that the two lineages could have 
emerged in response to the variation in gastrointestinal 
inflammation and microbiota disruptions. The dcuA gene 
is a fumarate/aspartate:H+ symporter and 90% of iso-
lates from the dcuB-negative clade contained the L212F 
mutation in the dcuA gene, whilst all isolates belonging 
to the dcuB-containing clade contained the S148F muta-
tion in this gene. However, it is unclear how these muta-
tions affect the function of this transporter. DcuA and 
DcuB work in close association with the cytoplasmic-
facing fumarate reductase FrdABC, but no mutations 
were found in the frdA, frdB or frdC genes [30]. Never-
theless, the absence of DcuB would prevent correct stoi-
chiometric exchange of succinate and fumarate that allow 
FrdABC to function. Campylobacter also has a unidi-
rectional fumarate reductase that cannot oxidize succi-
nate, MfrABE, that operates independently of DcuA and 
DcuB, as it is periplasm-facing [31]. For the clade with 
an intact dcuB gene, three out eighteen of the isolates 
contained a truncated mfrA gene due to a frameshift. It 
has been shown that FrdABC is the major contributor to 
fumarate reduction but that MfrABE is required for full 
fitness when the bacteria rely on fumarate respiration to 
conserve energy [31]. Taken together, these observations 
suggest that different clades will have distinct contribu-
tions of Dcu/Frd versus Mfr mediated fumarate respira-
tion during colonization. The role of DcuA and DcuB in 
aspartate uptake in low oxygen intestinal niches may also 
be physiologically important. Further work on the con-
centrations of gastrointestinal aspartate, succinate and 
fumarate in the patient and how this relates to the differ-
ent lineages is required to determine if gastrointestinal 
inflammation is creating distinct niches where certain 
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metabolites are not required. However, multiple other 
mutations were found amongst the two lineages and we 
cannot rule out the possibility that the mutations associ-
ated with dcuB were genetic hitchhikers.
C. jejuni ST45 is one of the most frequently isolated 
strains of Campylobacter collected from humans, domes-
tic animals and the environment [32–34]. It is regarded 
as a ‘generalist’ strain, as it has been isolated from multi-
ple host species and environments [35, 36], and has dem-
onstrated frequent host switching [37]. We found clades 
of ST45 that consisted of isolates collected from different 
sources, supporting ST45 as a generalist strain, but also 
found some clades that only consisted of isolates from 
single sources and many clades that only consisted of a 
single non-human source. Further analysis of non-human 
ST45 isolates is required to determine the extent that 
ST45 is a “generalist” strain.
The human microbiota is affected by disease [38], diet 
[39] and genetics [40]. Youmans et  al. [38] investigated 
the microbiota of individuals with traveler’s diarrhea and 
found that regardless of cause, diarrheic samples con-
tained a high Prevotella-to-Bacteroides (P/B) ratio. This 
observation is supported in this study, where the third 
diarrheal sample collected from the patient was higher 
on the Bristol scale (softer) and had a higher P/B ratio. 
Braun et  al. [41] investigated the microbiota of healthy 
individuals and hospitalized patients suspected of infec-
tious diarrhea, and found diarrhea patients were associ-
ated with an increased abundance of Proteobacteria. The 
first diarrheal sample collected from the patient had the 
highest Proteobacteria proportion, but this is because it 
has the highest Campylobacter proportion which made 
up most of the Proteobacteria in the microbiota of this 
sample. Zhuang et al. [42] found that diarrhea brought on 
by irritable bowel syndrome resulted in increased Bacte-
roidetes and decreased Firmicutes, such as with the first 
two samples. However, the amount of Prevotella and Pro-
teobacteria in the microbiota is also affected by diet [39, 
43]. Further microbiota samples and dietary information 
from the time of collection are required to investigate the 
role of disease and diet on the patient’s microbiota.
The sampled ancestor model identified multiple iso-
lates from the United Kingdom patient that represented 
ancestors to other isolates collected from this patient, 
but it detected no likely ancestors amongst the New 
Zealand patient’s isolates. This suggests that the popu-
lation of Campylobacter was more diverse within the 
New Zealand patient than within the United Kingdom 
patient, and therefore sampled isolates were less likely 
to represent an ancestral state. However, Campylobac-
ter within these patients have likely undergone multiple 
bottlenecks, especially with antimicrobial therapies [8, 
9], and we cannot rule out the possibility that the United 
Kingdom patient was sampled during several of these 
bottlenecks when the genetic diversity was smaller, whilst 
the New Zealand patient was not.
Campylobacter collected from the New Zealand patient 
had a substitution rate twice that of those collected from 
the United Kingdom patient, with no overlap between 
95% HPD intervals. Multiple differences were found in 
genes involved in DNA replication and repair between 
isolates collected from these patients. The mutS gene had 
the largest number of differences, but knockouts in this 
gene in the closely related bacterium, Helicobacter pylori, 
are not associated with increased substitution rates [44]. 
Mutations in mutY have been associated with faster sub-
stitution rates in Campylobacter [45, 46], but isolates col-
lected from the long-term patients had identical mutY 
genes. Further work is required to determine the effects 
of other mutations in DNA replication and repair genes 
on the substitution rate of Campylobacter.
The New Zealand patient’s gastrointestinal health, 
amount of inflammation and immunosuppression var-
ied significantly between the three samples obtained, as 
indicated by the variation in serum IgA, IgG, IgM and 
CRP concentrations, and fecal calprotectin concentra-
tion. Apart from the association between the proportion 
of each clade isolated and fecal calprotectin concentra-
tions, no other associations were identified between 
these markers, the fecal Campylobacter concentration, 
microbiota constitution, and the proportion of each 
clade isolated. The variation in these biochemical tests 
over these five months does suggest that the patient 
was undergoing changes in gastrointestinal health and 
immunosuppression.
An original objective of this research was to deter-
mine if Campylobacter was contributing to the patient’s 
diarrheal episodes or simply colonizing the patient. The 
lack of evidence for anti-Campylobacter antibodies sug-
gests that the patient had not mounted an immune 
response against the Campylobacter. However, most 
studies on Campylobacter serology have focused on 
acute infections, rather than the possible chronic infec-
tion described here. In addition, most serological tests 
have a high false-negative rate and for those individuals 
that do seroconvert the antibody titer quickly decreases 
after a few months [47, 48]. Studies on acute Guillain-
Barré syndrome, a disease often triggered by Campylo-
bacter infections have found up to 80% of cases display 
serological evidence of Campylobacter, but it is unclear 
whether the negative cases were triggered by Campylo-
bacter or other infections [49], and false positives have 
been observed [50]. Regarding the New Zealand patient, 
this could be explained by a number of scenarios includ-
ing: the Campylobacter was not the cause of any pathol-
ogy and had not been presented to the immune system 
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or triggered an immune response; the Campylobacter 
contributed to the diarrheal episodes but the patient was 
unable to form an immune response sufficient to remove 
the bacteria or be detected using the serological method 
described.
Conclusions
In this study we investigated the genomes of Campylo-
bacter from two patients that were both colonized for 
over a decade and found that multiple selective pressures 
were imposed on the Campylobacter. There was some 
evidence of genome degradation, but more evidence that 
Campylobacter adapted through the accumulation of 
non-synonymous SNPs and frameshifts in genes involved 
in cell motility, signal transduction and the major outer 
membrane protein, possibly to evade host defenses. 
However, we also found that the Campylobacter collected 
from the patients differed in substitution rates and diver-
sity as evidenced by sampled ancestral states, although 
the reason for these differences remains unclear. Through 
16S rRNA metabarcoding and biochemical markers we 
demonstrated that the New Zealand patient displayed a 
large amount of variation in their microbiome, inflamma-
tion and immunosuppression over five months, and that 
the Campylobacter collected from the patient could be 
divided into two subpopulations, the proportion of which 
correlated with the amount of gastrointestinal inflam-
mation. This suggests that subpopulations of Campylo-
bacter evolve within the gastrointestinal tract to adapt to 
changing environments. Overall, this study demonstrates 
how genomics, phylogenetics, 16S rRNA metabarcoding 
and biochemical markers can provide insight into how 




The previously described New Zealand patient [8] was 
invited to take part in a year-long study to investigate the 
effect of long-term Campylobacter colonization. Every 
month serum and fecal samples were collected from the 
patient. The Bristol fecal chart was used to grade the con-
sistency of the fecal sample [51]. Approximately 100 mg 
of fecal sample was set aside for immediate Campylobac-
ter culturing. The rest of the fecal sample and the serum 
sample were stored at −80 °C until all samples were col-
lected and were then further analyzed in a single batch.
Campylobacter quantification
Approximately 100  mg of each fecal sample was resus-
pended in 9.9 ml of phosphate-buffered saline (PBS) (pre-
pared in house). The reconstituted solution was serially 
diluted three times by adding 1 ml of sample to 9 ml of 
PBS, before 100  µl of each dilution was spirally plated 
onto modified charcoal-cefoperazone-deoxycholate agar 
(mCCDA) (Fort Richard Laboratories, Auckland, New 
Zealand) in duplicate. For plates that contained 50–500 
colonies, the number of colonies was quantified and used 
to calculate the concentration of Campylobacter in the 
fecal samples. From each sample, 3–6 Campylobacter 
colonies underwent genomic DNA extractions and were 
whole genome sequenced as previously described [8] 
using the Illumina MiSeq platform (Illumina, San Diego, 
California, United States).
Serum biochemistry and serology
The SERION ELISA classic Campylobacter jejuni IgA, 
IgG and IgM tests (Institut Virion\Serion GmbH, Wur-
zburg, Germany) were used to calculate the amount of 
anti-Campylobacter immunoglobulin A (IgA), immuno-
globulin G (IgG) and immunoglobulin M (IgM) in the 
serum according to the manufacturer’s instructions. An 
aliquot of each serum sample was sent to MedLab Cen-
tral (Palmerston North, New Zealand), who quantified 
the total serum IgA, IgG and IgM, and the serum inflam-
mation marker, C-reactive protein (CRP), on a Cobas 
8000 modular analyzer with the c702 module (Roche, 
Basel, Switzerland).
Fecal biochemistry
An aliquot of each fecal sample was sent to Canterbury 
Health Laboratories to quantify the amount of the gas-
trointestinal inflammation marker, calprotectin, using the 
Calpro Calprotecin ELISA (Calpro AS, Lysaker, Norway).
16S rRNA gene‑based microbiota analysis
The DNeasy PowerSoil Kit (Qiagen, Hilden, Germany) 
was used to extract DNA from an aliquot of each fecal 
sample. PCR was used to amplify the 16S V3-V4 region 
of bacterial DNA in the extracts and libraries were made 
from the 16S rRNA gene amplicons using a single-step 
PCR with barcoded primers [52]. The libraries were 
sequenced on an Illumina MiSeq as 2 × 250 paired-end 
reads. The reads were investigated with the MG-RAST 
pipeline [53].
ST45 pan genome analysis
The accession numbers of available C. jejuni ST45 
genome sequences were identified by searching the 
PATRIC database [54] and the Sequence Read Archive 
(SRA; https:// www. ncbi. nlm. nih. gov/ sra) for “Campylo-
bacter”, “ST45” and “Paired-end reads”. The raw reads of 
these sequences were downloaded and trimmed along 
with those collected from the patient using Trimmo-
matic v0.39 [55]. ARIBA v2.14.4 [56] was used to deter-
mine the sequence type of these reads using the C. jejuni 
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multi-locus sequence type (MLST) [57], and all isolates 
that were identified as ST45 were taken forward for fur-
ther analysis (Additional file 1).
The trimmed reads of all ST45 isolates were assembled 
using Spades v3.14.0 [58], and the assemblies produced 
were analyzed using Quast v5.0.2 [59] and CheckM 
v1.1.2 [60]. All assemblies that contained more than 300 
contigs greater than 500 bp or had more than 50 dupli-
cate genes were regarded as potentially contaminated or 
not sequenced at a high enough read depth and were not 
analyzed further.
The assemblies that passed QC were annotated using 
Prokka v1.12 [61] and the pan-genome evaluated using 
Roary v3.11.2 [62] with a 95% identity cut-off. Genes that 
were found in over 95% of the isolates were classified as 
part of the core genome. A maximum likelihood tree 
was constructed from single nucleotide polymorphisms 
(SNPs) in the core gene alignment using RAxML v8.2.11 
[63]. Annotation, pan-genome evaluation and phyloge-
netics were repeated with reference genome NC_002163 
[64] to root the tree. TreeCluster v1.0.1 [65] was used to 
predict clades in the maximum likelihood tree.
RFPlasmid v0.0.16 [66] was run on all assemblies with 
the “Campylobacter” database. Contigs with > 0.6 votes 
for plasmid were classified as “plasmid-associated”. Abri-
cate v1.0.1 (https:// github. com/ tseem ann/ abric ate) with 
the ResFinder [67] and virulence finder database (VFDB) 
[68] were used to search plasmid-associated contigs for 
AMR and virulence genes. Mob-typer [69] v3.0.0 was 
used to determine the mobility of the plasmid-associated 
contigs.
The ResFinder database, VFDB database, Plasmid-
Finder database [70], and a custom database consisting 
of all genes clustered by Roary were used with ARIBA to 
identify the presence of acquired AMR genes, virulence 
genes, plasmids and pseudogenes, respectively, in the 
ST45 genomes. Pseudogenes were identified from the 
custom database using the method described by Mather 
et al. [71]. Pseudogenes were analyzed if the original gene 
or pseudogene were found in 95% of isolates. To iden-
tify mutations associated with macrolide or fluoroqui-
nolone resistance, an ARIBA database was formed from 
the 23S rRNA and gyrA genes of C. jejuni NCTC 11168 
(NC_002163).
Genes and pseudogenes were classified as “long-term 
patient-specific” if they were found in 95% of isolates 
collected from the New Zealand and United Kingdom 
patients and fewer than 5% of ST45 isolates collected 
from other sources or other human sources. EggNOG 
v4.5.1 [72] was used to predict the function of the genes. 
Linear regression models were used to model the total 
number of genes and pseudogenes with source and 
country as the explanatory variables. Isolates where the 
country or source were unknown were excluded from 
the model, as were singletons. The long-term patients 
contained multiple isolates for a sample, so the mean 
number of genes and pseudogenes for these patients was 
modeled. Partial-F tests were used to determine if these 
variables had a significant effect on the model.
For the long-term New Zealand patient, linear regres-
sion models were used to model the total number of 
genes and pseudogenes with date of collection and clade 
as the explanatory variables. For samples where multiple 
isolates were collected, the mean number of genes and 
pseudogenes for each clade was calculated. Partial-F tests 
were used to determine if inclusion of clades had a sig-
nificant effect on the model.
The trimmed reads of the genome sequences col-
lected from the New Zealand patient and those belong-
ing to the most closely related clade, were aligned to the 
ST45 reference genome NC_022529 using Snippy v4.4.5 
(https:// github. com/ tseem ann/ snippy). Areas of putative 
recombination were removed from the full alignments 
produced using Gubbins [73]. RAxML was used to form 
a maximum likelihood tree from the non-recombinant 
SNPs identified.
Within‑patient ST45 phylogenetics
The trimmed reads of all genomes that were collected 
from the New Zealand patient were aligned to the ST45 
reference genome NC_022529 using Snippy and areas 
of putative recombination were removed from the full 
alignments produced using Gubbins. To determine if 
there was a clock signal, IQ-TREE v1.6.12 [74] was used 
to form a maximum likelihood tree from the identified 
non-recombinant SNPs and TempEst v1.5.3 [75] was 
used to test for temporal signal.
The non-recombinant SNPs were exported into BEAUti 
v2.5 to create an Extensive Markup Language (XML) 
file for BEAST v2.5 [76]. The ST45 reference genome 
NC_022529, consists of 584,548 adenine, 254,724 cyto-
sine, 253,882 guanine and 576,175 thymine nucleotides; 
these nucleotide proportions (adjusted for the SNPs) 
were added as non-varying sites to keep the model rep-
resentative of ST45 genomes and to calculate the sub-
stitution rate. bModelTest [77] was used to choose the 
substitution model (Supplementary Material). Multiple 
molecular clock (strict, random [78] and uncorrelated 
relaxed [79]) and tree models (constant and Extended 
Bayesian Skyline) [80]) were trialled for 100 million steps. 
Nested sampling [81] was used to select the model. A 
Generalized Time Reversible (GTR) [82] model was used 
to model nucleotide substitutions, an Extended Bayes-
ian Skyline model was used to model the effective popu-
lation size, and a strict clock model was used to model 
the molecular clock and was calibrated by the tip dates. 
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A uniform prior was placed on the substitution rate that 
it would not exceed  10–4 substitutions  site−1   year−1 nor 
fall below  10–8 substitutions  site−1   year−1 [83], and due 
to the large number of constant sites added, the propor-
tion of invariant sites was assumed to be zero. The XML 
file was run in BEAST in three separate chains with dif-
ferent starting seeds of 50 million steps each, before Log-
Combiner v2.5 was used to combine the runs with a 10% 
burn-in removed. Tracer v1.6 [84] was used to visualize 
the results.
TreeAnnotator v2.5 was used to form a maximum clade 
credibility tree of the SNP dataset. Evolview v2 [85] was 
used to visualize and edit the tree. The Sampled Ancestor 
(SA) v2.02 model [86] was also run in BEAST2 to deter-
mine the likelihood that any of the isolates collected from 
the patient represented ancestral states.
Second long‑term Campylobacter patient
The ST45 isolates downloaded included 22 genomes from 
an immunosuppressed long-term Campylobacter patient 
from the United Kingdom [9]. The phylogentic analyses 
outlined above were also performed on these isolates.
Phase variation and non‑synonymous SNPs
To investigate phase variation, Tatajuba v1.0.2 [87] was 
used to align the trimmed reads of all the ST45 isolates 
to the reference genome, NC_022529, and identify tracts 
that differed in size between the isolates. A cut-off of 0.95 
was used when comparing frameshifts between different 
groups of ST45 isolates to account for small proportions 
of sequencing errors. To investigate non-synonymous 
SNPs, Snippy was used  to align the trimmed reads of 
all the ST45 isolates to the same reference genome and 
identify SNPs that resulted in amino acid changes. 
Frameshifts and SNPs from long-term patient isolates 
were compared to ST45 isolates from other sources or 
other human sources as above to determine if they were 
associated with long-term patients.
Replication genes
To identify possible reasons for variation in substitu-
tion rates between isolates from each long-term patient, 
KEGG (https:// www. genome. jp/ kegg/) was searched for 
all genes involved in Campylobacter DNA replication and 
repair. An ARIBA database was created from these genes 
and used to search all the ST45 isolates for their presence 
and mutations in these genes. Mutations found in > 95% 
of isolates in one patient and < 5% of isolates in the other 
were classified as associated with a patient.
Stably‑inherited genetic changes
To identify genetic changes that were stably-inherited, 
non-synonymous SNPs, frameshifts and gene loss were 
identified in the Campylobacter colonizing the long-
term patients that were found in all isolates collected 
after a time point and not in any prior to this time point. 
Genetic changes that occurred between the collection of 
the first and second isolates, and last and second-to-last 
isolates were ignored as their stability was based on one 
isolate.
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